Drug intelligence / Profile preview

mutant KRAS vaccine

Development stage
Unknown
Lead developer
Elicio Therapeutics
Modality
Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Injection
01

Overview

A therapeutic cancer vaccine designed to target tumors with mutations in the KRAS gene, which is a driving force in many cancers. This vaccine works by activating immune cells that specifically target different KRAS mutations, particularly KRAS-G12D and KRAS-G12R, which drive approximately 90% of KRAS-mutated cancers. The vaccine contains synthesized peptides (short chains of amino acids) that can launch immune cells to target cancer cells with these mutations. It is administered as an injection in four places—one in each arm and leg, with the peptides traveling to nearby lymph nodes to generate an immune response. Unlike some other cancer vaccines that are custom-made for each patient using mRNA technology, this KRAS vaccine is designed to be more accessible, faster to administer, and less expensive.

Other names
KRAS peptide vaccineKVaxpooled mutant-KRAS peptide vaccineKRAS-targeted vaccineSPL mKRASvaxELI-002ELI002ELI 002
02

Targets

MHC I (MHC class I})Kirsten rat sarcoma viral oncogene homolog mutant neoepitopes presented by human leukocyte antigen class IKRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on mutant KRAS vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mutant KRAS vaccine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call